A growing number of clinical trials now are going beyond conventional randomized control measurements to collect self-reported outcomes focusing on improving patients’ involvement by including their perspectives throughout the drug development process. But while interest in developing and applying patient-reported outcomes (PROs) across the post-market spectrum is growing, progress has been slow.